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A B S T R A C TBackground: The US Food and Drug Administration (FDA) provides
formal guidance for the use of patient-reported outcomes (PROs) in
support of labeling claims, whereas the European Medicines Agency
(EMA) offers insight in a reﬂection paper relating to health-related
quality of life in lieu of formal guidance. Objectives: PRO label claims
granted for new molecular entities and biologic license applications
from 2006 through 2010 were reviewed to evaluate consistencies and
discrepancies in PRO label claims granted by the FDA and the EMA
and to highlight trends in the acceptance of PRO claims across
agencies. Methods: Products approved by both the FDA and the
EMA were identiﬁed. By using US Drug Approval Packages and Euro-
pean Public Assessment Reports packages, any PRO label claims made
for the same product by the same company were compared. Results:
Both agencies approved a total of 75 products. Of these, 35 (47%) had
at least one EMA-granted PRO label claim compared with 14 (19%) by
the FDA. Most FDA-grated claims focused on symptoms; however,see front matter Copyright & 2013, International S
r Inc.
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ndence to: Carla DeMuro, RTI Health Solutions, 304EMA-granted claims were more likely to include higher order con-
cepts. Few (12%) were granted the same label claims. Despite this
discordance between the two agencies, where PRO label
claims were granted by both the FDA and the EMA, there was
similarity in the type of label claim. Conclusions: The EMA is more
likely than the FDA to grant PRO claims and for higher order
constructs. On a macro level, there appears to be poor concordance
between claims granted by both agencies. On close examination,
however, there appears to be greater concordance than previously
recognized, which may be instructive in formulating future PRO
strategies. Further research to create strategic alignment across
agencies may be beneﬁcial.
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In late 2009, the US Food and Drug Administration (FDA) issued
formal guidance, Patient-Reported Outcome Measures: Use in Medical
Product Development to Support Labeling Claims [1], that set standards
for the use of patient-reported outcome measures (PROMs) in
support of product labeling claims. This guidance was intended to
“increase efﬁciency of discussions with the FDA during the
medical product development process, streamline the FDA’s
review of PRO instrument adequacy and resultant PRO data
collected during a clinical trial, and provide optimal information
about the patient perspective for use in making conclusions about
treatment effect at the time of medical product approval” [1].
Related to this effort, a second initiative for drug development
tools (DDTs) including patient-reported outcomes (PROs) was
created by the Center for Drug Evaluation and Research as part
of the FDA’s Critical Path Initiative [2]. The purpose of this
initiative was to provide a framework to facilitate the developmentand regulatory acceptance of scientiﬁc tools used in drug develop-
ment programs. The guidance for this initiative is currently at
draft stage but is intended to encompass multiple levels of
instrumentation including PROs, biomarkers, animal models, and
other clinical outcome assessments.
The European Medicines Agency (EMA), unlike the FDA, has
not issued formal guidelines speciﬁc to PROs but instead offered a
reﬂection paper [3] to provide broad recommendations on health-
related quality-of-life (HRQOL) evaluation in the context of
clinical trials. In addition, the EMA has developed the Biomarker’s
Qualiﬁcation program (2008) that is somewhat similar to the DDT
guidance in the United States. This qualiﬁcation program pro-
vides a formal mechanism for ratifying clinical trial endpoints,
including new or existing PROs [4].
Despite input into PROM standards from both the FDA and the
EMA, there still appears to be disparity in the use and acceptance
of PROMs in product labeling between the two agencies. It
appears from early analyses that the EMA is more likely to grantociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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Table 1 – Number of products with PRO label claims
approved by both the FDA and the EMA (2006–2010).
FDA EMA
Number of products with PRO label
claims
14 (19%) 35 (47%)
Number of PRO label claims granted 22 48
Total number of products approved by
both agencies (2006–2010)
75 75
EMA, European Medicines Agency; FDA, Food and Drug Adminis-
tration; PRO, patient-reported outcome.
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 1 1 5 0 – 1 1 5 5 1151claims in the area of HRQOL or functioning, whereas claims in the
United States are largely limited to claims of improvement in
symptoms [5–7].
A review of PRO label claims from the United States showed that
approximately 25% of product labels between 2006 and 2010 included
PRO endpoints [6]. Coombs et al. [8] compared PRO claims by the FDA
and the EMA for oncology products. To our knowledge, however, a
formal comparison of all PRO label claims for products approved by
both the FDA and the EMA is yet to be conducted. Therefore, the
purpose of this article was to compare and contrast product labeling
claims for new drug entities or biologic license agents approved by
the FDA and the EMA in the years 2006 through 2010.Methods
The FDA Drug Approval Reports Web site was used to identify ﬁrst
approvals of new drugs that were approved in the United States
from January 2006 through December 2010, including only those
products classiﬁed by the Center for Drug Evaluation and Research
as new molecular entities or biologic licensed agents. Any product
containing substances previously marketed with a different brand
name or set of indications, as a different dosage form or strength,
or as a combination product of previously marketed entities was
excluded. This product list was then compared with the EMA Web
site listing of authorized products. In the United States, Drug
Approval Packages (DAPs) and approved product labels were
reviewed. Information was retrieved from the medical review,
summary review, cross-discipline team leader review, and other
review sections from the DAP and from the Indication and Clinical
Studies section of the approved product label. The DAPs were
located on the FDA Web site Drugs@FDA (www.accessdata.fda.
gov). In the European Union (EU), European Public Assessment
Reports (EPAR) packages, the summary of product characteristics,
and scientiﬁc discussion documents found on EMA Web site
(www.ema.europa.eu) were reviewed.
For analysis purposes, PRO label claims were classiﬁed as one
of the following ﬁve types: symptoms, functioning, HRQOL,
patient global rating (PGR), or “other.” As previously described
[6], symptoms measures are deﬁned as measures of ”impair-
ments,” that is, any loss or abnormality of psychological, phys-
iological, or anatomical structure or function [9]. Measures of
functioning included activity limitation PROs that address phys-
ical, social, or psychological functioning, that is, any restriction or
lack of ability to perform an activity in the manner or within the
range considered normal for a human [9]. HRQOL has been
deﬁned as “the capacity to perform the usual daily activities for
a person’s age and major social role” [9]. Its emphasis is on the
measurement of a combination of symptoms and functioning
and, as such, HRQOL relates to health status. Consequently,
measures of HRQOL are multidimensional, yielding a proﬁle of
scores. A product label may contain more than one PRO claim.
Statistical analysis consisted of frequencies and cross-
tabulations of measured characteristics. Calculations were per-
formed by using Microsoft Excel 2007. For analysis purposes, if a
PRO appeared in the DAP or the EPAR, it was considered to be an
attempt to seek a PRO label claim, despite sponsor intent, unless
speciﬁcally noted otherwise.Results
A total of 156 new drugs were approved between January 2006
and December 2010 [6]. Of these, 37 were excluded from analysis
(33 generic products and 4 new products that were approved but
had no data available on the FDA Web site at the time of review).
Of the remaining 116 products, a total of 75 had been approved byboth the FDA and the EMA. Table 1 shows that of these, 35 (47%)
were granted at least one PRO claim by the EMA as compared to
14 (19%) by the FDA, representing a more than twofold increase in
at least one PRO label claim granted by the EMA. Table 1 also
shows that of the 70 PRO claims granted for the 35 products
approved by both agencies, 48 (69%) were granted by the EMA.
Products approved with at least one PRO label by either of the two
agencies are listed in Table 2. The table shows that for all
products for which the FDA granted a PRO label claim, the EMA
did as well. Also, 14 products with PRO label claims were
approved by both agencies and 10 of these products were
approved by the EMA ﬁrst and then by the FDA.
Table 3 summarizes the type of PRO claim granted by the FDA
or the EMA. The table shows that the EMA granted PRO label
claims to more products than did the FDA between 2006 and
2010. The majority of the claims in the United States focused on
symptoms; however, claims granted by the EMA included higher
order concepts such as HRQOL and functioning (EMA ¼ 22;
FDA ¼ 7).
A total of 52 PRO label claims were granted by both agencies
(FDA ¼ 22; EMA ¼ 30) for 14 products. Despite this discordance
between the number of PRO label claims granted by the two
agencies, concordance is found when label types (e.g., symptoms
and functioning) are analyzed for products with PRO label claims
granted by both the FDA and the EMA. Table 4 shows that for the
14 products with PRO label claims granted by both agencies, the
type of PRO claims granted was similar: 12 of the 14 products had
symptom claims granted by both agencies as were 5 functioning
claims and 3 PGR claims. HRQOL-related claims were granted for
Soliris and Letairis by both the FDA and the EMA. Drugs such as
Arcalyst and Toviaz demonstrate the concordance in symptom
labeling, with both the EU and FDA claims describing changes in
symptoms scores.
Table 4 provides a listing of the type of PRO claim granted by
each agency as well as the instruments used to secure the claim
for the 14 products with at least one PRO label claim from the
FDA and the EMA.
In addition, 21 products were granted PRO label claims by the
EMA but not the FDA. Within these products bearing no FDA
claims, 13 were granted HRQOL/QOL or functioning claims, 3
were granted treatment satisfaction, 5 were granted symptom
claims, and the remainder of the claims were based on PGR
questions. The Appendix in Supplemental Materials found at
http://dx.doi.org/10.1016/j.jval.2013.08.2293 provides a listing of
measures that were used in support of these claims.Discussion
This review provides the ﬁrst attempt to compare all FDA-granted
PRO label claims in approved products with all EMA-granted PRO
label claims since the release of the FDA’s ﬁnal guidance in the
recent past. At ﬁrst glance, the two agencies appear to agree on
Table 2 – PRO claims—FDA as compared to EMA by product (2006–2010).
Product FDA US approval date EMA EU approval date
Azilect Yes 5/16/2006 Yes 2/21/2005
Chantix Yes 5/10/2006 Yes 9/26/2006
Lucentis No 6/30/2006 Yes 1/22/2007
Omnaris Yes 10/20/2006 Yes 3/19/2008
Invega No 12/19/2006 Yes 3/4/2011
Soliris Yes 3/16/2007 Yes 6/20/2007
Neupro No 5/9/2007 Yes 2/15/2006
Torisel No 5/30/2007 Yes 11/19/2007
Letairis Yes 6/15/2007 Yes 4/21/2008
Micera No 11/14/2007 Yes 7/20/2007
Arcalyst Yes 2/27/2008 Yes 10/23/2009
Cimzia Yes 4/22/2008 Yes 10/1/2009
Lexiscan No 4/10/2008 Yes 9/6/2010
Toviaz Yes 10/8/2006 Yes 4/20/2007
Rapaﬂo Yes 10/8/2008 Yes 1/29/2010
Vimpat Yes 10/8/2008 Yes 8/29/2008
Banzel Yes 11/14/2008 Yes 1/16/2007
Aﬁnitor No 3/30/2009 Yes 8/3/2009
Simponi Yes 4/24/2009 Yes 10/1/2009
Samsca No 5/19/2009 Yes 8/3/2009
Ilaris No 6/17/2009 Yes 10/23/2009
Extavia No 8/14/2009 Yes 5/20/2008
Saphris No 8/13/2009 Yes 9/1/2010
Stelara No 9/25/2009 Yes 1/16/2009
Arzerra No 10/26/2009 Yes 4/19/2010
Votrient No 10/19/2009 Yes 6/14/2010
Ampyra Yes 1/22/2010 Yes 7/20/2011
Acterma Yes 1/8/2010 Yes 1/16/2009
Xiaﬂex No 2/2/2010 Yes 2/28/2011
Treanda No 3/20/2008 Yes 3/19/2010
Vpriv No 2/26/2010 Yes 8/26/2010
Carbaglu No 3/18/2010 Yes 1/24/2003
Zortress No 4/20/2010 Yes 3/08/2009
Lumizyme No 5/24/2010 Yes 3/29/2006
Jevtana No 6/17/2010 Yes 3/17/2011
EMA, European Medicines Agency; EU, European Union; FDA, Food and Drug Administration; PRO, patient-reported outcome.
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approved products. On close inspection within the 14 products
that had claims from both agencies, however, similarities in
labeling exist. The majority of these 14 (91%), while not havingTable 3 – Summary of PRO label claim types granted
by the FDA or the EMA (2006–2010).
Type of claim n (%)
FDA-granted
claims (N ¼ 14
products)
EMA-granted
claims (N ¼ 35
products)
Symptoms 12 (54) 19 (40)
Functioning 5 (23) 9 (19)
HRQOL 2 (9) 13 (27)
Patient global rating 3 (14) 5 (10)
Other 0 (0) 2 (4)
Total claims 22 (100) 48 (100)
EMA, European Medicines Agency; FDA, Food and Drug Adminis-
tration; HRQOL, health-related quality of life; PRO, patient-
reported outcome.the exact wording included in the claim, offered the same type of
claim. For example, symptom or functioning claims may have
been granted by both agencies but with slight differences in
wording. In 12 of the 14 products, symptom claims were granted
by both agencies with the exception of Letairis, which received a
claim for dyspnea by the EMA, and Ampyra, which received a
functioning claim by both agencies.
Concordance between the two agencies can be understood in
part by examination of the available guidance documents. The
EMA broadly accepts patient assessed measurement of core
symptoms of disease with no speciﬁc regulatory requirement
for these endpoints [10]. This position aligns closely with the FDA
position described in the PRO guidance that notes that the
“question of what to measure may be obvious given the condition
being treated.” The guidance further elucidates this comment by
using the effect on the treatment of pain as an example in which
a symptom is readily recognized and accepted to support labeling
claims. Given how close the agencies align in this acceptance, it is
not unexpected to see concordance for symptom claims. In
addition, differences in the symptoms claims may be fairly
readily explained. The FDA has publicly taken a position that
the concept of fatigue is multidimensional and therefore is not
endorsed, whereas the EMA has accepted fatigue as a measurable
concept. This is demonstrated by the fatigue claim granted to
Table 4 – Types of PRO label claims approved by the FDA and the EMA for the 14 products with claims granted
by both agencies (2006–2010).
EMA Total
PRO type Symptom Function HRQOL PGR Other None
FDA Symptom Azilect 12
Chantix
Omnaris
Soliris
Arcalist
Cimzia
Toviaz
Rapaﬂo
Vimpart
Banzil
Simponi
Acterma
Function Azilect 5
Cimzia
Simponi
Ampyra
Acterma
HRQOL Soliris 2
Letairis
PGR Banzil 3
Simponi
Acterma
Other 0
None Letaris Arcalist Azilect Toviaz Cimzia 0
Cimzia
Simponi
Acterma
Total 13 6 6 4 1 0 EMA ¼ 30
FDA ¼ 22
EMA, European Medicines Agency; FDA, Food and Drug Administration; HRQOL, heath-related quality of life; PGR, patient global rating; PRO,
patient-reported outcome.
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 1 1 5 0 – 1 1 5 5 1153Simponi by the EMA and not by the FDA. Finally, as noted by
Girman et al. [5], it is important to recognize that regulatory
requirements for registration often differ by regions, causing
sponsors to launch multiple trials with differing endpoints to
meet health authority requirements outside of both the FDA and
the EMA. In some instances, these decisions may be more closely
aligned with EMA guidance than with the FDA.
As anticipated by previous research [7], the EMA granted a
greater number of higher order claims including HRQOL and
functioning (Table 5). This difference is often widely discussed
among peers and can be a point of contention for clinical teams
planning a single PRO strategy for both the United States and the
EU. It is helpful to recognize that this difference in acceptance
rates may be in part due to the request in some EMA guidance
documents to include HRQOL measures as key secondary end-
points. Within these guidance documents, the EMA will recom-
mend speciﬁc, validated instruments for use within the
therapeutic area, and so in a sense lend endorsement to these
measures. The FDA, however, instead typically recommends the
identiﬁcation of concepts and does not endorse speciﬁc meas-
ures. Given the FDA position on the complex and multidimen-
sional deﬁnition of HRQOL, the measurement of these concepts
may not be recommended by the FDA and hence not endorsed as
a claim. In addition, the EMA is open to claims of improved
physical functioning based on the subset of domains within
HRQOL measures [10], whereas the FDA would not likely accept
such a basis for a functioning claim.Azilect, Lucentis, Stelara, and Samsca provide instructive
examples where the EMA granted HRQOL or functioning claims
on the basis of measures that were rejected by the FDA. The FDA
denied a HRQOL claim based on the PD-Qualif scale for Azilect
noting that “the sponsor did not make statistically appropriate
adjustments for these multiple comparisons” [11]; however, the
EMA granted a claim of “signiﬁcant and beneﬁcial effect in quality
of life” on the basis of the same scale. The VFQ-25 supported a
claim of “patient reported beneﬁts” for Lucentis by the EMA,
whereas the FDA questioned whether the tool was ﬁt for purpose.
Stelara received no PRO claims in the United States but did
receive endorsement for all claims sought by the EMA including
HRQOL and symptoms (Dermatology Life Quality Index , short-
form 36 health survey, Itch visual analogue scale). Finally, the
EMA granted a HRQOL claim for Samsca on the basis of results
from the short-form 12 health survey, noting that “mental scores
showed statistically signiﬁcant and clinically relevant improve-
ments for tolvaptan treatment compared to placebo.” A Study
Endpoints and Label Development group review for Samsca,
however, indicates that “The primary endpoint ‘the SF-12’ was
developed as a generic health status instrument for the general
population and not as a symptom assessment tool or HRQoL tool
in patients with hyponatremia.”
Ampyra received FDA marketing approval in January 2010
followed by conditional approval (marketed as Fampyra) by the
EMA in July 2011. The EMA provided conditional approval
because of concerns about the clinical relevance of the MS
Table 5 – Higher order claims granted by the EMA
(2006–2010).
Product PRO measure Claim type
Azilect Parkinson’s Disease
Quality of Life Scale
HRQOL
Soliris EORTC-QLQ-C30 HRQOL
Letaris SF-36 and Borg HRQOL, symptoms
Lucentis VFQ-25 HRQOL (patient-
reported beneﬁts)
Torisel EQ-5D questionnaire QALY
Treanda EORTC-C30 and EORTC-
QLQ-CLL25
HRQOL
Cimzia HAQ-DI, Fatigue
Assessment Scale, SF-
36, Work Productivity
Survey
HRQOL, functioning,
work productivity
Aﬁnitor EORTC-QLQ-C30 QOL
Simponi HAQ, SF-36, FACIT-Fatigue
Scale
Functioning, HRQOL
Samsca SF-12 HRQOL (mental
component)
Stelara DLQI, Itch VAS, SF-36,
HADS, Work Limitations
Questionnaire
HRQOL, Work
productivity
Extavia FAMS No beneﬁt but
assessed and
included in the
SPC
Votrient EORTC-QLQ-C30 and EQ-
5D questionnaire
HRQOL (no
difference
between groups)
DI, Disability Index; DLQI, Dermatology Life Quality Index; EMA,
European Medicines Agency; EORTC-C30, European Organization
for Research & Treatment of Cancer Quality of Life Questionnaire
Core 30; EORTC-QLQ-C30, European Organization for Research &
Treatment of Cancer Quality of Life Questionnaire Core 30; EORTC-
QLQ-CLL25, European Organization for Research & Treatment of
Cancer Quality of Life Questionnaire chronic lymphocytic leuke-
mia; EQ-5D, EuroQol ﬁve-dimensional; FACIT, Functional Assess-
ment of Chronic Illness Therapy; FAMS, Functional Assessment
MS Treatment; HADS, Hospital Anxiety and Depression Scale;
HAQ, Health Assessment Questionnaire; HRQOL, heath-related
quality of life; PRO, patient-reported outcome; QALY, quality-
adjusted life-year; QOL, quality of life; SF-12, short-form 12 health
survey; SF-36, short-form 36 health survey; SPC, summary of
product characteristics; VAS, visual analogue scale; VFQ-25, Visual
Function Questionnaire 25.
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blinded, placebo-controlled, long-term efﬁcacy and safety study
to investigate a broader primary endpoint clinically meaningful
in terms of walking ability …” A Study Endpoints and Label
Development review noted a similar concern with the clinical
relevance and effect on the responder rate of the MS Walking
Scale based on lack of signiﬁcant difference on a patient global
“how do you feel about the effects of the study medication over
the past 7 days?” (scale 0–7, where 0 was “terrible” and 7
“delighted”); however, a “walking speed” label claim was granted.
Such examples appear to indicate that differing levels of
evidence are needed to facilitate positive reviews by agencies.
Importantly, in all instances in which higher order claims
(HRQOL, functioning) were granted by the FDA, they were also
granted by the EMA, suggesting that if the evidence to support a
claim is deemed sufﬁcient in the United States, it is likely to besufﬁcient for the EMA as well. Given the small number of these
claims, however, this should be interpreted with caution and as
always, clinical teams should carefully assess the speciﬁc meas-
ure and its context of use.
Similar ﬁndings are noted for treatment satisfaction tools. The
EMA granted two treatment satisfaction claims to products that
did not receive PRO labeling by the FDA (Xiaﬂex and Zortress).
Finally, it is important to note the limitations of this research.
For analysis purposes, if a sponsor included a PRO in a DAP or an
EPAR, it was assumed that a claim was sought. PROs are often
included in clinical trials for reasons beyond labeling [5,9], and so
this assumption may have skewed results somewhat. However,
given the proprietary nature of labeling discussions, the true
intent of a sponsor is often unknown to outside observers. In
addition, the guidance documents (including the EMA reﬂection
paper, FDA PRO guidance, and Biomarker and DDT Qualiﬁcation
programs) are all fairly recent regulatory developments. The
effect of these guidance documents on trials planned before their
release is unknown and perhaps is yet to materialize.Conclusions
The EMA is more likely than the FDA to grant PRO claims and is
more likely to grant claims for higher order constructs such as
HRQOL and functioning. On a macro level, there appears to be
poor concordance between claims granted by both agencies. This
discrepancy in granting claims may necessitate that sponsors
develop agency-speciﬁc PRO strategies, adding strain to limited
resources and time required for drug development programs. On
close examination, however, there appears to be areas of greater
concordance than previously recognized for symptoms claims
and functioning, which may be instructive in formulating future
PRO strategies. Further research to understand where there is
strategic alignment across agencies may be beneﬁcial or help
identify when multiple PRO strategies are needed or if a single
approach may be found acceptable by both agencies.Source of ﬁnancial Support: This study was supported by
Novartis Pharmaceuticals.Supplemental Materials
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